Previous studies have demonstrated that PTPRD is downregulated by genetic (homozygous deletion, loss-of-function mutation, and copy number loss) and epigenetic (miRNA and methylation) modifications in different types of human cancers, including glioblastoma, colon cancer, breast cancer, lung cancer, and head and neck squamous cell carcinoma [6–11]. This evidence concerns the gene PTPRD and breast carcinoma.